The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma.
 
Joseph Clark
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Novartis; Pfizer; Prometheus
Consulting or Advisory Role - Argos Therapeutics; Novartis; Prometheus
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer; Prometheus
Research Funding - Bristol-Myers Squibb; Prometheus
 
Marc S. Ernstoff
No Relationships to Disclose
 
Mohammed M. Milhem
Consulting or Advisory Role - Amgen; Genentech
 
Christopher D. Lao
No Relationships to Disclose
 
David H. Lawson
Research Funding - Prometheus
 
Lawrence E. Flaherty
Consulting or Advisory Role - Genomic Health; Merck; Roche/Genentech
 
Theresa L. Luna
Employment - Prometheus
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Prometheus
 
Sandra Aung
Employment - Prometheus
Stock and Other Ownership Interests - Bristol-Myers Squibb; Cell Genesys; Merck; UbiVac
Patents, Royalties, Other Intellectual Property - UbiVac
Travel, Accommodations, Expenses - Prometheus